About HepaRegeniX GmbH
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
working for us?
Check out our latest job postings:
Dr. Wolfgang Albrechtp388971
Dr. Birgit Jungp388971
Dr. David Shapirop388971
Dr. Markus Weissbachp388971
Prof. Andreas Buschp388971
Board of Directors
Elias Papatheodorou, Chairman of the Board
Prof. Dr. Lars Zender, University Hospital Tubingen
Prof. Dr. Johannes Zanzinger, BIVF
Dr. Emmanuelle Coutanceau, Novo Holdings A/S
Vera Mehler, Coparion
Prof. Dr. Thomas Knittel, Independent Board member